Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + platinum
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Albumin-bound paclitaxel + platinum refers to the combination of albumin-bound (nanoparticle) paclitaxel (commonly known as nab-paclitaxel or by the brand name Abraxane) with a platinum-based chemotherapy agent such as carboplatin or cisplatin. Albumin-bound paclitaxel is a solvent-free formulation of the microtubule inhibitor paclitaxel, in which the drug is bound to human serum albumin nanoparticles to enhance delivery and reduce toxicity compared to conventional formulations[2][3][6]. Platinum agents like carboplatin and cisplatin are DNA-damaging agents that form DNA crosslinks and inhibit DNA synthesis. The combination is used primarily for advanced non-small cell lung cancer (NSCLC), where it has demonstrated improved response rates over conventional regimens[4]. It may also be studied or used off-label in other solid tumors.
- Brand names
- Abraxane
- Other names
- nab-paclitaxel + platinumprotein-bound paclitaxel + platinumnanoparticle albumin–bound paclitaxel + platinum
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on albumin-bound paclitaxel + platinum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + platinum.